| Literature DB >> 28649544 |
Priscila Nicolao Mazzola1,2, Bruno Costa Teixeira3, Gabriel Henrique Schirmbeck3, Alvaro Reischak-Oliveira3, Terry G J Derks2, Francjan J van Spronsen2, Carlos Severo Dutra-Filho1,4, Ida Vanessa Doederlein Schwartz5,6.
Abstract
BACKGROUND: In phenylketonuria, dietary treatment prevents most of the severe brain disease. However, patients have to follow a diet restricted in several natural components, what may cause decreased bone density and obesity. Exercise is known to improve both mental functioning and bone density also avoiding obesity, and could optimize aspects of central and peripheral outcome, regardless changes in phenylalanine (Phe) levels. However, the acute effects of exercise on metabolic parameters in phenylketonuria patients are unknown and thereby long-term adaptations are unclear. Therefore, this study aimed to evaluate patients' basal metabolic rate (BMR), and their acute response to an aerobic exercise session on plasma concentrations of Phe, tyrosine (Tyr), and branched-chain amino acids (BCAA), as well as metabolic and hormonal responses.Entities:
Keywords: Aerobic exercise; BCAA, branched-chain amino acids; BMI, body mass index; BMR, basal metabolic rate; Basal metabolic rate; CTL, control; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N/A, not applicable; NS, non-significant; Natural restricted diet; PKU; PKU, phenylketonuria; Phe, phenylalanine; Phenylalanine; Phenylketonuria; RER, respiratory exchange ratio; Tyr, tyrosine; VCO2, carbon dioxide production; VO2, oxygen consumption; VO2peak, peak oxygen consumption
Year: 2015 PMID: 28649544 PMCID: PMC5471389 DOI: 10.1016/j.ymgmr.2015.10.003
Source DB: PubMed Journal: Mol Genet Metab Rep ISSN: 2214-4269
Fig. 1Experimental design.
In fasted state, participants went to the lab twice (at day 0 and day 1). In the day 0, participants performed the basal metabolic rate (BMR) test, followed by blood sampling for plasma phenylalanine (Phe) evaluation (0), breakfast and 30-min rest. Then the peak oxygen consumption (VO2peak) test was performed. In the day 1, blood sampling was collected at moment 1 (M1), then participants received breakfast, waited 30-min in rest and performed the aerobic exercise session. Immediately after exercise (moment 2, M2), the last blood sample was collected.
Clinical characteristics from control (CTL) and phenylketonuria (PKU) groups at day 0.
| CTL | PKU | p value | |
|---|---|---|---|
| Gender (male:female) | 12:5 | 7:2 | NS |
| Age (years) | 22 ± 4 (17) | 21 ± 4 (9) | NS |
| BMI (kg/m2) | 23 ± 2 (17) | 24 ± 3 (9) | NS |
| Phenylalanine (μmol/L) | 57 ± 14 (17) | 562 ± 141 (9) | < 0.001 |
| BMR (kcal/kg/day) | 21 ± 4 (17) | 23 ± 4 (9) | NS |
| RER during BMR | 0.87 ± 0.07 (17) | 0.82 ± 0.07 (9) | NS |
| VO2peak (mL/kg/min) | 31 ± 6 (17) | 28 ± 8 (9) | NS |
| Workload peak (W) | 216 ± 49 (17) | 203 ± 31 (9) | NS |
BMI, body mass index, BMR, basal metabolic rate, RER, respiratory exchange ratio, VO2peak, peak oxygen consumption, NS, non-significant. Data for numeric variables are expressed as mean ± SD (n). See methodology for details on the statistical analysis.
Biochemical parameters at moments 1 (M1) and 2 (M2) in controls (CTL) and phenylketonuria (PKU) patients.
| M1 | CTL M1 vs PKU M1 | M2 | CTL M1 vs CTL M2 | PKU M1 vs PKU M2 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CTL | PKU | p value | CTL | PKU | p value | p value | |||||
| Phe (μmol/L) | 81 ± 24 | (17) | 773 ± 190 | (8) | < 0.001 | 73 ± 15 | (17) | 723 ± 139 | (8) | NS | NS |
| Tyr (μmol/L) | 57 ± 15 | (17) | 62 ± 9 | (8) | NS | 79 ± 20 | (17) | 90 ± 24 | (8) | < 0.001 | NS |
| Phe/Tyr ratio | 1.4 ± 0.2 | (17) | 12.4 ± 2.4 | (8) | < 0.001 | 1.0 ± 0.2 | (17) | 8.3 ± 1.8 | (8) | < 0.001 | NS |
| Tryptophan (μmol/L) | 35 ± 9 | (17) | 29 ± 6 | (8) | NS | 35 ± 8 | (17) | 36 ± 12 | (8) | NS | NS |
| BCAA (μmol/L) | 456 ± 86 | (17) | 332 ± 50 | (8) | 0.001 | 403 ± 63 | (17) | 478 ± 132 | (8) | NS | NS |
| Glucose (mg/dL) | 89 ± 8 | (17) | 83 ± 7 | (8) | NS | 77 ± 9 | (17) | 78 ± 11 | (8) | 0.001 | NS |
| Lactate (mg/dL) | 1.3 ± 0.5 | (17) | 1.3 ± 0.3 | (7) | NS | 3.7 ± 1.6 | (17) | 3.6 ± 1.8 | (7) | < 0.001 | NS |
| Triacylglycerol (mg/dL) | 89 ± 33 | (17) | 76 ± 27 | (8) | NS | 100 ± 39 | (17) | 77 ± 27 | (8) | NS | NS |
| Total cholesterol (mg/dL) | 168 ± 31 | (17) | 121 ± 26 | (8) | 0.001 | 181 ± 34 | (17) | 129 ± 26 | (8) | < 0.001 | < 0.001 |
| HDL (mg/dL) | 54 ± 12 | (17) | 42 ± 6 | (8) | NS | 57 ± 11 | (17) | 45 ± 7 | (8) | < 0.001 | NS |
| LDL (mg/dL) | 97 ± 28 | (17) | 63 ± 19 | (8) | NS | 103 ± 28 | (17) | 68 ± 19 | (8) | 0.001 | 0.001 |
| Dopamine (pg/mL) | 56 ± 15 | (17) | 58 ± 17 | (8) | NS | 57 ± 13 | (17) | 57 ± 11 | (8) | NS | NS |
| Noradrenaline (pg/mL) | 228 ± 77 | (17) | 220 ± 52 | (8) | NS | 229 ± 85 | (17) | 217 ± 53 | (8) | NS | NS |
| Adrenaline (pg/mL) | 49 ± 15 | (17) | 45 ± 12 | (8) | NS | 52 ± 15 | (17) | 43 ± 11 | (8) | NS | NS |
| Adiponectin (ng/mL) | 28 ± 6 | (14) | 37 ± 8 | (8) | NS | 30 ± 9 | (14) | 39 ± 4 | (7) | NS | NS |
Phe, phenylalanine; Tyr, tyrosine; BCAA, branched chain amino acids (isoleucine, leucine, and valine); RER, respiratory exchange ratio; NS, non-significant; N/A, not applicable. Results are expressed as mean ± SD (n), two-sided paired t-test. After applying Bonferroni correction, only results with p < 0.002 were considered significant (see methodology).
Fig. 2Actual oxygen consumption (VO2) during the 30-min exercise in controls (CTL) and well and poorly controlled phenylketonuria (PKU) patients. Data are expressed as mean ± SD of percentage of prescribed VO2, n = 16 for controls, n = 5 and n = 3 for well and poorly controlled PKU subgroups, respectively.